Compare Danaher Corporation (DHR) vs S&P500 ETF (SPY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs S&P500 ETF — how do they compare? Danaher Corporation trades at $219.87 (market cap $152.87B), while S&P500 ETF trades at $778.54 (market cap $821.54B). The key difference: S&P500 ETF is far larger — about 5.4× Danaher Corporation's market cap, and Danaher Corporation pays a 0.74% dividend while S&P500 ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Danaher Corporation for 69 Days and S&P500 ETF for 205 Days on average.
| DHR | SPY | |
|---|---|---|
Market Cap | $152.87B | $821.54B |
Volume | 5,228,698 | 40,070,358 |
Sector | Health | — |
52-Week High | $242.05 | $779.14 |
52-Week Low | $161.91 | $631.99 |
Typical Hold Time | 69 Days | 205 Days |
Enterprise Value | $175.08B | — |
Dividend Yield | 0.74% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $217.46, down 0.47% on the day, with a bullish technical signal from moving averages and support at $214. The company shows strong profitability with a 58.51% gross margin and has beaten EPS estimates for three consecutive quarters. Recent news includes a declared $0.40 dividend payable in October 2026 and significant institutional buying, such as Bank of America's new $993.8 million stake in Q2 2026.
The outlook is positive with a consensus price target of $230.31, implying 5.9% upside, supported by 70% analyst buy ratings. Risks include elevated valuation multiples like a P/E of 38.76 and fluctuating cash flows, but earnings growth in biotechnology and steady revenue provide a solid foundation for investor confidence.
SPY, tracking the S&P 500, trades at $773.97, down 0.42% on the day amid mixed market signals. Technical indicators show a bullish trend with moving averages supporting upside momentum, while oscillators remain neutral. The ETF's fundamentals are tied to the broad U.S. equity market, with no specific company financials available, and a future dividend of $1.89 scheduled for October 2026. Recent news highlights concerns over valuation and profit growth expectations for 2027.
The outlook for SPY is cautiously optimistic, driven by bullish technical trends and seasonal patterns, but risks include potential earnings growth slowdown and elevated market valuations. Investors may find opportunity in broad market exposure, though vigilance on macroeconomic indicators and corporate profit trends is warranted.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About S&P500 ETF
The ETF is designed to track the performance of the securities and the stocks in the S&P 500 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on SPY →
